For some patients who are newly diagnosed with metastatic lung cancer, the combination of a treatment that helps the immune system to fight cancer—an immunotherapy—and chemotherapy may help them to live longer than chemotherapy alone, according to the results of a large clinical trial carried out in the US.
Read more about the treatment and the survival rates.
The drug involved, Pembrolizumab (Keytruda), is already used to treat certain types of cancer. A clinical trial in the UK in 2015/16 studied its effectiveness in patients with Hodgkin lymphoma.